tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TSE:NRX Stock Latest News

NurExone Biologic to Showcase Exosome Therapies Globally
Company AnnouncementsNurExone Biologic to Showcase Exosome Therapies Globally
8d ago
NurExone’s Breakthrough Extends Spinal Injury Treatment Window
PremiumCompany Announcements
NurExone’s Breakthrough Extends Spinal Injury Treatment Window
13d ago
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
PremiumPress Releases
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
14d ago
NurExone Biologic Inc. Showcases Corporate Growth and Q2 Results
PremiumCompany Announcements
NurExone Biologic Inc. Showcases Corporate Growth and Q2 Results
23d ago
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress Releases
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
23d ago
NurExone Spotlights ExoPTEN Therapy at Key Conferences
PremiumCompany AnnouncementsNurExone Spotlights ExoPTEN Therapy at Key Conferences
28d ago
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Premium
Press Releases
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
28d ago
NurExone Biologic Advances in Exosome Production
Premium
Company Announcements
NurExone Biologic Advances in Exosome Production
1M ago
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
PremiumPress Releases
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
1M ago
NurExone’s ExoPTEN Shows Precise Injury Targeting
PremiumCompany Announcements
NurExone’s ExoPTEN Shows Precise Injury Targeting
1M ago
NurExone’s ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
PremiumPress Releases
NurExone’s ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
1M ago
NurExone Advances ExoPTEN Drug Towards Clinical Trials
PremiumCompany Announcements
NurExone Advances ExoPTEN Drug Towards Clinical Trials
2M ago
NurExone Biologic Expands Patent Portfolio and Partnerships
PremiumCompany AnnouncementsNurExone Biologic Expands Patent Portfolio and Partnerships
2M ago
NurExone’s ExoPTEN Shows Promise for Glaucoma Treatment
Premium
Company Announcements
NurExone’s ExoPTEN Shows Promise for Glaucoma Treatment
2M ago
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
Premium
Press Releases
Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
2M ago
NurExone Unveils Website and Conference Spotlight
PremiumCompany Announcements
NurExone Unveils Website and Conference Spotlight
3M ago
Updates from NurExone: Growth Conference Presentation and Website Relaunch
PremiumPress Releases
Updates from NurExone: Growth Conference Presentation and Website Relaunch
3M ago
NurExone Targets Vision Loss with ExoPTEN Therapy
PremiumCompany Announcements
NurExone Targets Vision Loss with ExoPTEN Therapy
3M ago
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
PremiumPress Releases
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
3M ago
NurExone Biologic Uplifted by Drug Development Expert
PremiumCompany AnnouncementsNurExone Biologic Uplifted by Drug Development Expert
3M ago
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Premium
Press Releases
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
3M ago
NurExone Secures Japanese Patent for ExoPTEN
Premium
Company Announcements
NurExone Secures Japanese Patent for ExoPTEN
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >